Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity

Biomaterials

Volumn 34, Issue 16, 2013, Pages 4089-4097

  Shahin, Mostafa ^a   Soudy, Rania ^a   Aliabadi, Hamidreza M ^a   Kneteman, Norman ^a   Kaur, Kamaljit ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Active targeting; Breast cancer; Doxorubicin; Peptide density; Stealth liposomes; Targeting peptide

Indexed keywords

ACTIVE TARGETING; BREAST CANCER; DOXORUBICIN; STEALTH LIPOSOMES; TARGETING PEPTIDES;

CELL CULTURE; CELLS; CYTOTOXICITY; DISEASES; LIGANDS; LIPOSOMES; MAMMALS; TUMORS;

PEPTIDES;

DOXORUBICIN; DRUG CARRIER; LIGAND; LIPOSOME; P18 4 PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TUMOR LEVEL; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; IC 50; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; SCID MOUSE; SPLEEN; TUMOR VOLUME; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; LIGANDS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN ENGINEERING; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 84874995544     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.02.019     Document Type: Article

References (31)

1. Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol Appl Pharmacol 2008, 229:121-134.
2. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009, 30:592-599.
3. Ning Y.M., He K., Dagher R., Sridhara R., Farrell A.T., Justice R., et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology 2007, 21:1503-1508.
4. Thigpen J.T., Aghajanian C.A., Alberts D.S., Campos S.M., Gordon A.N., Markman M., et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005, 96:10-18.
5. Solomon R., Gabizon A.A. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma Leuk 2008, 8:21-32.
6. Sapra P., Moase E.H., Ma J., Allen T.M. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res. 2004, 10:1100-1111.
7. Sapra P., Allen T.M. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res. 2004, 10:2530-2537.
8. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 2006, 66:10073.
9. Shahin M, Soudy R, El-Sikhry H, Seubert JM, Kaur K, Lavasanifar A. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin. Cancer Lett, in press.
10. Reddy J.A., Abburi C., Hofland H., Howard S.J., Vlahov I., Wils P., et al. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther 2002, 9:1542-1550.
11. Saul J.M., Annapragada A., Natarajan J.V., Bellamkonda R.V. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003, 92:49-67.
12. Shmeeda H., Mak L., Tzemach D., Astrahan P., Tarshish M., Gabizon A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther 2006, 5:818-824.
13. Kawano K., Maitani Y. Effects of polyethylene glycol spacer length and ligand density on folate receptor targeting of liposomal doxorubicin in vitro. J Drug Deliv 2011, 2011:160967.
14. Olivier V., Meisen I., Meckelein B., Hirst T.R., Peter-Katalinic J., Schmidt M.A., et al. Influence of targeting ligand flexibility on receptor binding of particulate drug delivery systems. Bioconjug Chem 2003, 14:1203-1208.
15. Gindy M.E., Ji S., Hoye T.R., Panagiotopoulos A.Z., Prud'homme R.K. Preparation of poly(ethylene glycol) protected nanoparticles with variable bioconjugate ligand density. Biomacromolecules 2008, 9:2705-2711.
16. Garg A., Tisdale A.W., Haidari E., Kokkoli E. Targeting colon cancer cells using pegylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm 2009, 366:201-210.
17. Ferrari M. Nanogeometry: beyond drug delivery. Nat Nanotechnol 2008, 3:131-132.
18. Soudy R., Gill A., Sprules T., Lavasanifar A., Kaur K. Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells. J Med Chem. 2011, 54:7523-7534.
19. Huang C., Mason J.T. Geometric packing constraints in egg phosphatidylcholine vesicles. Proc Natl Acad Sci U S A 1978, 75:308-310.
20. Marty C., Schwendener R.A. Cytotoxic tumor targeting with scFv antibody-modified liposomes. Adoptive immunotherapy: methods and protocols 2005, 389-401. Humana Pr Inc. B. Ludewig, M.W. Hoffmann (Eds.).
21. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 2005, 107:262-275.
22. Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv 2011, 8:565-580.
23. Askoxylakis V., Zitzmann S., Mier W., Graham K., Kramer S., von Wegner F., et al. Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clin Cancer Res 2005, 11:6705-6712.
24. Ahmad I., Longenecker M., Samuel J., Allen T.M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 1993, 53:1484.
25. Lopes de Menezes D.E., Pilarski L.M., Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998, 58:3320.
26. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002, 8:1172-1181.
27. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995, 1237:99-108.
28. Maruyama K., Takizawa T., Yuda T., Kennel S.J., Huang L., Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1995, 1234:74-80.
29. Allen T.M. Liposomal drug delivery. Curr Opin Colloid Interface Sci 1996, 1:645-651.
30. Gu F., Zhang L., Teply B.A., Mann N., Wang A., Radovic-Moreno A.F., et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A 2008, 105:2586-2591.
31. Shmeeda H., Tzemach D., Mak L., Gabizon A. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release 2009, 136:155-160.